ArticleFrontiers in aging neuroscience2026
Electroacupuncture inhibits pyroptosis to improve motor function in an MPTP-induced mouse model of Parkinson's disease.
Article in Frontiers in aging neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To investigate whether electroacupuncture (EA) ameliorates motor dysfunction and protects nigrostriatal dopaminergic neurons in Parkinson's disease (PD) mice by inhibiting NLRP3 inflammasome-mediated pyroptosis. Methods: Male C57BL/6 mice were randomly assigned before model induction to seven groups: saline-treated control, MPTP model, MPTP plus EA, MPTP plus Nigericin, MPTP plus EA and Nigericin, MPTP plus MCC950, and MPTP plus EA and MCC950 groups. Mice in the control group received equal-volume saline, whereas mice in the other six groups were administered 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP; 30 mg/kg, intraperitoneally) once daily for five consecutive days. Following model induction, EA was applied at Baihui (GV20) and Dazhui (GV14) at 100 Hz for 20 min per session over 14 days. Nigericin and MCC950 were used as an NLRP3 inflammasome activator and inhibitor, respectively. Motor function was assessed using the open-field and pole tests. Dopaminergic neuronal integrity, neuronal injury, microglial activation, and the cellular localization of NLRP3 were evaluated using immunohistochemistry, hematoxylin-eosin staining, and immunofluorescence. The expression levels of tyrosine hydroxylase, NLRP3, ASC, Caspase-1, and the N-terminal fragment of gasdermin D (GSDMD-N) were determined using immunofluorescence and western blotting. Results: EA alleviated abnormal open-field hyperlocomotion and prolonged pole-descent latency in MPTP-treated mice, preserved tyrosine hydroxylase-positive dopaminergic neurons in the substantia nigra, restored striatal tyrosine hydroxylase expression, and reduced neuronal injury and microglial activation. NLRP3 was predominantly colocalized with tyrosine hydroxylase-positive dopaminergic neurons, whereas limited colocalization was observed with IBA-1-positive microglia. Electroacupuncture significantly suppressed the MPTP-induced upregulation of NLRP3, ASC, Caspase-1, and GSDMD-N. Nigericin exacerbated motor abnormalities, nigrostriatal injury, and pyroptosis-related signaling and largely abolished the protective effects of EA. Conversely, MCC950 produced protective effects comparable to those of EA, whereas their combined administration provided no significant additional benefit. Conclusion: EA improves motor dysfunction and protects the nigrostriatal dopaminergic system in MPTP-induced PD mice, at least partly by suppressing NLRP3 inflammasome-mediated pyroptosis in dopaminergic neurons. These findings identify the NLRP3 inflammasome as an important mechanistic target underlying the neuroprotective effects of electroacupuncture in experimental PD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.